Natural killer cells in spontaneous control of HIV infection

Current Opinion in HIV and AIDS

Volumn 6, Issue 3, 2011, Pages 208-213

  Berger, Christoph T ^a,b   Alter, Galit ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

antibody depended cellular cytotoxicity; controller; HIV; killer immunoglobulin like receptors; long term nonprogressor; natural killer cells; non neutralizing antibodies

Indexed keywords

IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN;

ADAPTIVE IMMUNITY; ARTICLE; CELL FUNCTION; CELL MEDIATED CYTOTOXICITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INNATE IMMUNITY; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; VIRUS REPLICATION;

HIV; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; KILLER CELLS, NATURAL;

EID: 79955479979     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283457798     Document Type: Article

References (60)

1. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-640. (Pubitemid 33043908)
2. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187-376. (Pubitemid 20010960)
3. Alter G, Altfeld M. NK cells in HIV-1 infection: Evidence for their role in the control of HIV-1 infection. J Intern Med 2009; 265:29-42.
4. Bjorkstrom NK, Ljunggren HG, Sandberg JK. CD56 negative NK cells: Origin, function, and role in chronic viral disease. Trends Immunol 2010; 31:401-406.
5. Gerosa F, Baldani-Guerra B, Nisii C, et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195:327-333. (Pubitemid 34461490)
6. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008; 9:503-510. (Pubitemid 351560519)
7. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989; 320:1731-1735. (Pubitemid 19163129)
8. Orange JS. Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol 2006; 6:399-409. (Pubitemid 44714151)
9. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001; 1:41-49. (Pubitemid 33741974)
10. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225-274. (Pubitemid 40563170)
11. Chung A, Rollman E, Johansson S, et al. The utility of ADCC responses in HIV infection. Curr HIV Res 2008; 6:515-519.
12. Carrington M, Martin MP, van Bergen J. KIR-HLA intercourse in HIV disease. Trends Microbiol 2008; 16:620-627.
13. Alter G, Teigen N, Ahern R, et al. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 2007; 195:1452-1460. (Pubitemid 46717463)
14. Kim S, Sunwoo JB, Yang L, et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A 2008; 105:3053-3058. (Pubitemid 351723666)
15. Alter G, Rihn S, Walter K, et al. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol 2009; 83:6798-6805.
16. Alter G, Martin MP, Teigen N, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007; 204:3027-3036. (Pubitemid 350179568)
17. Thomas R, Apps R, Qi Y, et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 2009; 41:1290-1294.
18. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429-434. (Pubitemid 35154456)
19. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-740. (Pubitemid 46848586)
20. Yawata M, Yawata N, Draghi M, et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203:633-645.
21. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436:709-713. (Pubitemid 41117274)
22. Fernandez NC, Treiner E, Vance RE, et al. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005; 105:4416-4423. (Pubitemid 40720789)
23. Anfossi N, Andre P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331-342. (Pubitemid 44224147)
24. Schwartz O, Marechal V, Le Gall S, et al. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996; 2:338-342. (Pubitemid 26080655)
25. Cohen GB, Gandhi RT, Davis DM, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999; 10:661-671. (Pubitemid 29302919)
26. The International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-1557.
27. Limou S, Le Clerc S, Coulonges C, et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 2009; 199:419-426.
28. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-947. (Pubitemid 47301321)
29. Van Manen D, Kootstra NA, Boeser-Nunnink B, et al. Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS 2009; 23:19-28.
30. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197:563-571. (Pubitemid 351321534)
31. O'Connell KA, Han Y, Williams TM, et al. Role of natural killer cells in a cohort of elite suppressors: Low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J Virol 2009; 83:5028-5034.
32. Flores-Villanueva PO, Yunis EJ, Delgado JC, et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci U S A 2001; 98:5140-5145. (Pubitemid 32397096)
33. Boulet S, Kleyman M, Kim JY, et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS 2008; 22:1487-1491.
34. Johansson S, Johansson M, Rosmaraki E, et al. Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J Exp Med 2005; 201:1145-1155. (Pubitemid 40524682)
35. Long BR, Ndhlovu LC, Oksenberg JR, et al. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol 2008; 82:4785-4792. (Pubitemid 351657040)
36. Boulet S, Song R, Kamya P, et al. HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. J Immunol 2010; 184:2057-2064.
37. Vieillard V, Fausther-Bovendo H, Samri A, Debre P. Specific phenotypic and functional features of natural killer cells from HIV-infected long-term nonprogressors and HIV controllers. J Acquir Immune Defic Syndr 2010; 53:564-573.
38. Barker E, Martinson J, Brooks C, et al. Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. AIDS 2007; 21:2363-2365. (Pubitemid 350287473)
39. Mavilio D, Benjamin J, Daucher M, et al. Natural killer cells in HIV-1 infection: Dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A 2003; 100:15011-15016. (Pubitemid 37518008)
40. De Maria A, Fogli M, Costa P, et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol 2003; 33:2410-2418. (Pubitemid 37138973)
41. O'Connor GM, Holmes A, Mulcahy F, Gardiner CM. Natural killer cells from long-term nonprogressor HIV patients are characterized by altered phenotype and function. Clin Immunol 2007; 124:277-283. (Pubitemid 47247613)
42. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23:897-906.
43. Alsmadi O, Herz R, Murphy E, et al. A novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infection. J Virol 1997; 71:925-933. (Pubitemid 27030262)
44. Alter G, Teigen N, Davis BT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 2005; 106:3366-3369. (Pubitemid 41609166)
45. Mavilio D, Lombardo G, Benjamin J, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: A highly dysfunctional NK subset expanded in HIVinfected viremic individuals. Proc Natl Acad Sci U S A 2005; 102:2886-2891. (Pubitemid 40299886)
46. Brunetta E, Fogli M, Varchetta S, et al. The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood 2009; 114:3822-3830.
47. Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redistribution in HIV-1 infection: New insights in pathophysiology and clinical outcomes. J Leukoc Biol 2010; 88:1119-1130.
48. Johansson SE, Hejdeman B, Hinkula J, et al. NK cell activation by KIR-binding antibody 1-7F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients. Clin Immunol 2010; 134:158-168.
49. Vieillard V, Strominger JL, Debre P. NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci U S A 2005; 102:10981-10986. (Pubitemid 41105979)
50. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008; 1:23-30.
51. Paust S, Gill HS, Wang BZ, et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 2010; 11:1127-1135.
52. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009; 457:557-561.
53. Tiemessen CT, Shalekoff S, Meddows-Taylor S, et al. Natural killer cells that respond to human immunodeficiency virus type 1 (HIV-1) peptides are associated with control of HIV-1 infection. J Infect Dis 2010; 202:1444-1453.
54. Tiemessen CT, Shalekoff S, Meddows-Taylor S, et al. Cutting edge: Unusual NK cell responses to HIV-1 peptides are associated with protection against maternal-infant transmission of HIV-1. J Immunol 2009; 182:5914-5918.
55. Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009; 4:388-393.
56. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001; 75:6953-6961. (Pubitemid 32641582)
57. Brenner BG, Gryllis C, Wainberg MA. Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases. J Leukoc Biol 1991; 50:628-640.
58. Baum LL, Cassutt KJ, Knigge K, et al. HIV-1 gp120-specific antibodydependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996; 157:2168-2173. (Pubitemid 126449697)
59. Liu Q, Sun Y, Rihn S, et al. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol 2009; 83:8705-8712.
60. Xiao P, Zhao J, Patterson LJ, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2010; 84:7161-7173.